The MODE Trial: Planned Caesarean Section Versus Induction of Labour for Women With Class III Obesity (MODE)

The MODE Trial: A Pilot Trial Investigating Planned Caesarean Section Versus Induction of Labour for Women With Class III Obesity

Canadian guidelines recommend that women with a pre-pregnancy body mass index (BMI) at or above 40 kg/m2 deliver by their due date. When delivery is planned prior to spontaneous labour, there are two options: planned induction of labour or pre-labour Caesarean (C-section). However, it is not yet clear whether induction of labour or planned pre-labour C-section is the best option for this population.

The MODE Trial aims to assess the feasibility of conducting a larger-scale trial of planned mode of delivery in first time mothers who have a BMI >=40kg/m2, and obtain preliminary data on health outcomes for moms and babies following delivery by either planned C-section or induction of labour.

Study Overview

• Status: Unknown
• Conditions: Obesity; Pregnancy, High Risk; Cesarean Section Complications; Obesity Complicating Childbirth; Labor Onset and Length Abnormalities
• Intervention / Treatment: Procedure: Caesarean section; Procedure: Induction of Labour

Detailed Description

Women with obesity have a decreased likelihood of achieving vaginal delivery. According to the Centre for Maternal and Child Enquiries, the chance of spontaneous vaginal delivery in women with a BMI ≥35kg/m2 is 55%, while the chance is 36.7% in women with a BMI ≥40.0kg/m2. This number includes women who go into labour spontaneously, in which, the odds of a vaginal delivery are highest. The rate of failure to induce labour approaches 80% with increased complications and morbidity including abnormal fetal heart rate monitoring, labour dystocia, emergency C-section, and fetal macrosomia. It has been proposed that some women may benefit from a planned Caesarean section delivery. However, Caesarean sections are also not straightforward in women with obesity, and come with significant risks of short- and long-term morbidity for mother and baby, including prolonged operative times, higher volumes of blood loss and infection rates and higher rates of NICU admission.

Given that there are many considerations when deciding how to best deliver a woman with obesity, it is not surprising that there is a high degree of clinical equipoise. In reality, the decision is made jointly between the patient and her care provider, often guided by overall instinct and local resource availability.

Studies to date have been retrospective in nature. There is a significant need for prospective study of the outcomes and experiences of planned induction of labour and planned Caesarean section in women with obesity to allow evidence-based counselling and decision-making.

• Study Type: Interventional
• Enrollment (Anticipated): 100
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Ottawa, Ontario, Canada, K1H 8L6
      • The Ottawa Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Capability of participant to comprehend and comply with study requirements
• Age ≥18 years at time of consent
• Nulliparous (never given birth after 19+6/7 weeks of gestation)
• Pre-pregnancy BMI or calculated BMI obtained in the first 13 weeks of pregnancy ≥40kg/ m2
• Participant plans to give birth in a participating site
• Gestational age 34+0/7 - 36+6/7 weeks (based on estimated date of conception (EDC) assigned at the first ultrasound performed after 7+0/7 and prior to 20 +0/7 weeks)
• Live fetus, documented positive heart rate at visit 1 prior to randomization
• Singleton fetus in cephalic presentation at the time of randomization
• No maternal or fetal contraindications to vaginal delivery

Exclusion Criteria:

• Known major fetal anomaly, confirmed by ultrasound or genetic testing
• Multiple gestation
• Known documented evidence of alcohol or drug abuse in this current pregnancy
• Currently enrolled or has participated in another clinical trial within 3 months of the date of randomization (at discretion of Trial Coordinating Centre)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Randomized Caesarean section; Randomized to planned pre-labour Caesarean section	Procedure: Caesarean section; Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.; Other Names: C-section; Cesarean
Active Comparator: Randomized Induction of Labour; Randomized to planned induction of labour	Procedure: Induction of Labour; Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.
Active Comparator: Preference Caesarean section; Preference for planned pre-labour Caesarean section	Procedure: Caesarean section; Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.; Other Names: C-section; Cesarean
Active Comparator: Preference Induction of Labour; Preference for planned Induction of Labour	Procedure: Induction of Labour; Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility of conducting a larger-scale trial (eligibility criteria)	Appropriateness of eligibility criteria, measured by the reasons for exclusion of screened patients	18 months
Feasibility of conducting a larger-scale trial (recruitment rate)	Eligibility and recruitment rate, measured by the proportion of patients who are eligible and recruited into the trial	18 months
Feasibility of conducting a larger-scale trial (randomization)	Appropriateness of randomization, measured by the proportion of trial participants who consent to randomization	18 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maternal morbidity and mortality	Rates of: maternal death, admission to ICU, intrapartum Caesarean section, postpartum hemorrhage, postpartum wound infection, endometritis, venous thromboembolism (VTE), hypertensive disorders of pregnancy (gestational hypertension or preeclampsia), indication for Caesarean delivery, operative vaginal delivery, indication for operative vaginal delivery, uterine incision extensions during Caesarean section, chorioamnionitis, third or fourth degree perineal lacerations, induction agents, pain medication use during induction, labour, Caesarean section and postpartum.	Pregnancy to 6 week postpartum
Fetal and neonatal morbidity and mortality	Rates of: stillbirth, neonatal death, gestational age at birth, birthweight, need for respiratory support within 72 hours of birth, duration of respiratory support, 5 minute Apgar <7, hypoxic-ischemic encephalopathy, seizure, infection (confirmed sepsis or pneumonia), meconium aspiration syndrome, birth trauma (bone fracture, neurologic injury or retinal hemorrhage), cephalohematoma, intracranial or subgaleal hemorrhage, or hypotension requiring vasopressor support, breastfeeding rates, hypoglycemia requiring intravenous treatment, jaundice requiring treatment, need for transfusion.	Pregnancy to 6 week postpartum
Length of hospital stay	Length of hospital stay (in minutes) for both mom and baby	Start of induction to delivery; admission to delivery; and delivery until discharge, assessed up until 6-weeks postpartum
Hospital readmission rates	The proportion of mothers and/or infants re-admitted to the hospital	Delivery to 6-weeks postpartum
Techniques for induction of labour	What method was used for induction	Admission to hospital until delivery, assessed up to 7 days from hospital admission.
Maternal satisfaction	Maternal satisfaction with study design and procedures, measured by a survey	Approximately 48-hours post-birth and 42+/-7 days postpartum
Healthcare provider satisfaction	Healthcare provider satisfaction with study design and procedures, measured through a survey	18 months

Collaborators and Investigators

• Sponsor: Ottawa Hospital Research Institute
• Collaborators: Canadian Institutes of Health Research (CIHR)
• Investigators: Principal Investigator: Laura Gaudet, MD, MSc, The Ottawa Hospital; Study Director: Ruth Rennicks White, BScN, The Ottawa Hospital

Study record dates

Study Major Dates

• Study Start (Anticipated): September 1, 2019
• Primary Completion (Anticipated): August 31, 2020
• Study Completion (Anticipated): August 31, 2021

Study Registration Dates

• First Submitted: May 21, 2019
• First Submitted That Met QC Criteria: June 12, 2019
• First Posted (Actual): June 14, 2019

Study Record Updates

• Last Update Posted (Actual): June 14, 2019
• Last Update Submitted That Met QC Criteria: June 12, 2019
• Last Verified: June 1, 2019

More Information

Terms related to this study

• Keywords: obesity; pregnancy; C-section; labor; labour; induction; caesarean; cesarean
• Additional Relevant MeSH Terms: Overnutrition; Nutrition Disorders; Overweight; Body Weight; Obesity
• Other Study ID Numbers: CRRF ID 1469; FDN148438 (Other Grant/Funding Number: Canadian Institutes of Health Research)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No